The U.K.’s FTSE 100 hit a fresh record on Wednesday, and Barclays said investors should stay overweight London’s blue chip ...

Asian investors need to figure out where to put their trillions, and don’t want to over invest in the U.S., says Morgan ...

Alphabet is due to post its second-quarter earnings after Wednesday's closing bell. Investors will be focused on the state of ...

I am looking to retire at 62. I’m single with a 12-year-old daughter, splitting parenting time with my ex-wife. I pay $1,000 ...

Tesla's stock is down 18% so far this year, and some analysts wonder if the company will lower its full-year forecast when it ...

Japanese Prime Minister Shigeru Ishiba denied reports he plans to announce his resignation over a historic defeat of his ...

Have an issue with your financial planner or looking for a new one? Email questions or concerns to [email protected].

Solid Biosciences said federal regulators have granted its fast-track designation for the company's investigational gene therapy for the treatment of a heart rhythm condition.

Shares of Cambridge, Mass.-based Sarepta have fallen by more than 90% in the last year amid safety concerns about its Elevidys, a gene therapy that treats Duchenne muscular dystrophy, following ...

The threat of an all-out trade war between the U.S. and the E.U. has put European auto stocks in reverse throughout 2025. At ...

Dear Quentin, My husband is 40 and I am 44. When we got married a year ago, I was aware that he had about $67,000 in ...